AI in Cancer Immunotherapy Drugs Market Size, Share, and Trends 2026 to 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics

5.1.1. Market Drivers

5.1.2. Market Restraints

5.1.3. Market Opportunities

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining power of suppliers

5.2.2. Bargaining power of buyers

5.2.3. Threat of substitute

5.2.4. Threat of new entrants

5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis

6.1.2. Key Strategies Adopted by Players

6.1.3. Vendor Landscape

6.1.3.1. List of Suppliers

6.1.3.2. List of Buyers

Chapter 7. Global AI in Cancer Immunotherapy Drugs Market, By AI Technology

7.1. AI in Cancer Immunotherapy Drugs Market, by AI Technology

7.1.1. Machine Learning

7.1.1.1. Market Revenue and Forecast

7.1.2. Deep Learning

7.1.2.1. Market Revenue and Forecast

7.1.3. Generative AI

7.1.3.1. Market Revenue and Forecast

7.1.4. Natural Language Processing (NLP)

7.1.4.1. Market Revenue and Forecast

7.1.5. Computer Vision

7.1.5.1. Market Revenue and Forecast

Chapter 8. Global AI in Cancer Immunotherapy Drugs Market, By Drug Development Stage

8.1. AI in Cancer Immunotherapy Drugs Market, by Drug Development Stage

8.1.1. Target Identification & Validation

8.1.1.1. Market Revenue and Forecast

8.1.2. Lead Discovery

8.1.2.1. Market Revenue and Forecast

8.1.3. Preclinical Development

8.1.3.1. Market Revenue and Forecast

8.1.4. Clinical Trial Design & Optimization

8.1.4.1. Market Revenue and Forecast

8.1.5. Biomarker Discovery

8.1.5.1. Market Revenue and Forecast

Chapter 9. Global AI in Cancer Immunotherapy Drugs Market, By Immunotherapy Type

9.1. AI in Cancer Immunotherapy Drugs Market, by Immunotherapy Type

9.1.1. Immune Checkpoint Inhibitors

9.1.1.1. Market Revenue and Forecast

9.1.2. CAR-T Cell Therapies

9.1.2.1. Market Revenue and Forecast

9.1.3. Cancer Vaccines

9.1.3.1. Market Revenue and Forecast

9.1.4. Monoclonal Antibodies

9.1.4.1. Market Revenue and Forecast

9.1.5. Bispecific Antibodies

9.1.5.1. Market Revenue and Forecast

9.1.6. Cytokine-based Immunotherapies

9.1.6.1. Market Revenue and Forecast

9.1.7. Oncolytic Virus Therapies

9.1.7.1. Market Revenue and Forecast

9.1.8. Other Immunotherapies

9.1.8.1. Market Revenue and Forecast

Chapter 10. Global AI in Cancer Immunotherapy Drugs Market, By Cancer Type

10.1. AI in Cancer Immunotherapy Drugs Market, by Cancer Type

10.1.1. Lung Cancer

10.1.1.1. Market Revenue and Forecast

10.1.2. Breast Cancer

10.1.2.1. Market Revenue and Forecast

10.1.3. Colorectal Cancer

10.1.3.1. Market Revenue and Forecast

10.1.4. Melanoma

10.1.4.1. Market Revenue and Forecast

10.1.5. Prostate Cancer

10.1.5.1. Market Revenue and Forecast

Chapter 11. Global AI in Cancer Immunotherapy Drugs Market, By Application

11.1. AI in Cancer Immunotherapy Drugs Market, by Application

11.1.1. Drug Discovery

11.1.1.1. Market Revenue and Forecast

11.1.2. Biomarker Identification

11.1.2.1. Market Revenue and Forecast

11.1.3. Patient Stratification

11.1.3.1. Market Revenue and Forecast

11.1.4. Treatment Response Prediction

11.1.4.1. Market Revenue and Forecast

11.1.5. Combination Therapy Design

11.1.5.1. Market Revenue and Forecast

11.1.6. Clinical Trial Optimization

11.1.6.1. Market Revenue and Forecast

11.1.7. Personalized Immunotherapy

11.1.7.1. Market Revenue and Forecast

11.1.8. Adverse Event Prediction

11.1.8.1. Market Revenue and Forecast

Chapter 12. Global AI in Cancer Immunotherapy Drugs Market, By End User

12.1. AI in Cancer Immunotherapy Drugs Market, by End User

12.1.1. Pharmaceutical Companies

12.1.1.1. Market Revenue and Forecast

12.1.2. Biotechnology Companies

12.1.2.1. Market Revenue and Forecast

12.1.3. Contract Research Organizations

12.1.3.1. Market Revenue and Forecast

12.1.4. Academic & Research Institutes

12.1.4.1. Market Revenue and Forecast

12.1.5. Hospitals & Cancer Centers

12.1.5.1. Market Revenue and Forecast

Chapter 13. Global AI in Cancer Immunotherapy Drugs Market, By Cloud-based AI

13.1. AI in Cancer Immunotherapy Drugs Market, by Deployment Model

13.1.1. Cloud-based AI

13.1.1.1. Market Revenue and Forecast

13.1.2. On-premise AI

13.1.2.1. Market Revenue and Forecast

13.1.3. Hybrid AI

13.1.3.1. Market Revenue and Forecast

Chapter 14. Global AI in Cancer Immunotherapy Drugs Market, Regional Estimates and Trend Forecast

14.1. North America

14.1.1. Market Revenue and Forecast, by AI Technology

14.1.2. Market Revenue and Forecast, by Drug Development Stage

14.1.3. Market Revenue and Forecast, by Immunotherapy Type

14.1.4. Market Revenue and Forecast, by Cancer Type

14.1.5. Market Revenue and Forecast, by Application

14.1.6. Market Revenue and Forecast, by Deployment Model

14.1.7. Market Revenue and Forecast, by End User

14.1.8. U.S.

14.1.8.1. Market Revenue and Forecast, by AI Technology

14.1.8.2. Market Revenue and Forecast, by Drug Development Stage

14.1.8.3. Market Revenue and Forecast, by Immunotherapy Type

14.1.8.4. Market Revenue and Forecast, by Cancer Type

14.1.8.5. Market Revenue and Forecast, by Application

14.1.8.6. Market Revenue and Forecast, by Deployment Model

14.1.8.7. Market Revenue and Forecast, by End User

14.1.9. Rest of North America

14.1.9.1. Market Revenue and Forecast, by AI Technology

14.1.9.2. Market Revenue and Forecast, by Drug Development Stage

14.1.9.3. Market Revenue and Forecast, by Immunotherapy Type

14.1.9.4. Market Revenue and Forecast, by Cancer Type

14.1.9.5. Market Revenue and Forecast, by Application

14.1.9.6. Market Revenue and Forecast, by Deployment Model

14.1.9.7. Market Revenue and Forecast, by End User

14.2. Europe

14.2.1. Market Revenue and Forecast, by AI Technology

14.2.2. Market Revenue and Forecast, by Drug Development Stage

14.2.3. Market Revenue and Forecast, by Immunotherapy Type

14.2.4. Market Revenue and Forecast, by Cancer Type

14.2.5. Market Revenue and Forecast, by Application

14.2.6. Market Revenue and Forecast, by Deployment Model

14.2.7. Market Revenue and Forecast, by End User

14.2.8. UK

14.2.8.1. Market Revenue and Forecast, by AI Technology

14.2.8.2. Market Revenue and Forecast, by Drug Development Stage

14.2.8.3. Market Revenue and Forecast, by Immunotherapy Type

14.2.8.4. Market Revenue and Forecast, by Cancer Type

14.2.8.5. Market Revenue and Forecast, by Application

14.2.8.6. Market Revenue and Forecast, by Deployment Model

14.2.8.7. Market Revenue and Forecast, by End User

14.2.9. Germany

14.2.9.1. Market Revenue and Forecast, by AI Technology

14.2.9.2. Market Revenue and Forecast, by Drug Development Stage

14.2.9.3. Market Revenue and Forecast, by Immunotherapy Type

14.2.9.4. Market Revenue and Forecast, by Cancer Type

14.2.9.5. Market Revenue and Forecast, by Application

14.2.9.6. Market Revenue and Forecast, by Deployment Model

14.2.9.7. Market Revenue and Forecast, by End User

14.2.10. France

14.2.10.1. Market Revenue and Forecast, by AI Technology

14.2.10.2. Market Revenue and Forecast, by Drug Development Stage

14.2.10.3. Market Revenue and Forecast, by Immunotherapy Type

14.2.10.4. Market Revenue and Forecast, by Cancer Type

14.2.10.5. Market Revenue and Forecast, by Application

14.2.10.6. Market Revenue and Forecast, by Deployment Model

14.2.10.7. Market Revenue and Forecast, by End User

14.2.11. Rest of Europe

14.2.11.1. Market Revenue and Forecast, by AI Technology

14.2.11.2. Market Revenue and Forecast, by Drug Development Stage

14.2.11.3. Market Revenue and Forecast, by Immunotherapy Type

14.2.11.4. Market Revenue and Forecast, by Cancer Type

14.2.11.5. Market Revenue and Forecast, by Application

14.2.11.6. Market Revenue and Forecast, by Deployment Model

14.2.11.7. Market Revenue and Forecast, by End User

14.3. APAC

14.3.1. Market Revenue and Forecast, by AI Technology

14.3.2. Market Revenue and Forecast, by Drug Development Stage

14.3.3. Market Revenue and Forecast, by Immunotherapy Type

14.3.4. Market Revenue and Forecast, by Cancer Type

14.3.5. Market Revenue and Forecast, by Application

14.3.6. Market Revenue and Forecast, by Deployment Model

14.3.7. Market Revenue and Forecast, by End User

14.3.8. India

14.3.8.1. Market Revenue and Forecast, by AI Technology

14.3.8.2. Market Revenue and Forecast, by Drug Development Stage

14.3.8.3. Market Revenue and Forecast, by Immunotherapy Type

14.3.8.4. Market Revenue and Forecast, by Cancer Type

14.3.8.5. Market Revenue and Forecast, by Application

14.3.8.6. Market Revenue and Forecast, by Deployment Model

14.3.8.7. Market Revenue and Forecast, by End User

14.3.9. China

14.3.9.1. Market Revenue and Forecast, by AI Technology

14.3.9.2. Market Revenue and Forecast, by Drug Development Stage

14.3.9.3. Market Revenue and Forecast, by Immunotherapy Type

14.3.9.4. Market Revenue and Forecast, by Cancer Type

14.3.9.5. Market Revenue and Forecast, by Application

14.3.9.6. Market Revenue and Forecast, by Deployment Model

14.3.9.7. Market Revenue and Forecast, by End User

14.3.10. Japan

14.3.10.1. Market Revenue and Forecast, by AI Technology

14.3.10.2. Market Revenue and Forecast, by Drug Development Stage

14.3.10.3. Market Revenue and Forecast, by Immunotherapy Type

14.3.10.4. Market Revenue and Forecast, by Cancer Type

14.3.10.5. Market Revenue and Forecast, by Application

14.3.10.6. Market Revenue and Forecast, by Deployment Model

14.3.10.7. Market Revenue and Forecast, by End User

14.3.11. Rest of APAC

14.3.11.1. Market Revenue and Forecast, by AI Technology

14.3.11.2. Market Revenue and Forecast, by Drug Development Stage

14.3.11.3. Market Revenue and Forecast, by Immunotherapy Type

14.3.11.4. Market Revenue and Forecast, by Cancer Type

14.3.11.5. Market Revenue and Forecast, by Application

14.3.11.6. Market Revenue and Forecast, by Deployment Model

14.3.11.7. Market Revenue and Forecast, by End User

14.4. MEA

14.4.1. Market Revenue and Forecast, by AI Technology

14.4.2. Market Revenue and Forecast, by Drug Development Stage

14.4.3. Market Revenue and Forecast, by Immunotherapy Type

14.4.4. Market Revenue and Forecast, by Cancer Type

14.4.5. Market Revenue and Forecast, by Application

14.4.6. Market Revenue and Forecast, by Deployment Model

14.4.7. Market Revenue and Forecast, by End User

14.4.8. GCC

14.4.8.1. Market Revenue and Forecast, by AI Technology

14.4.8.2. Market Revenue and Forecast, by Drug Development Stage

14.4.8.3. Market Revenue and Forecast, by Immunotherapy Type

14.4.8.4. Market Revenue and Forecast, by Cancer Type

14.4.8.5. Market Revenue and Forecast, by Application

14.4.8.6. Market Revenue and Forecast, by Deployment Model

14.4.8.7. Market Revenue and Forecast, by End User

14.4.9. North Africa

14.4.9.1. Market Revenue and Forecast, by AI Technology

14.4.9.2. Market Revenue and Forecast, by Drug Development Stage

14.4.9.3. Market Revenue and Forecast, by Immunotherapy Type

14.4.9.4. Market Revenue and Forecast, by Cancer Type

14.4.9.5. Market Revenue and Forecast, by Application

14.4.9.6. Market Revenue and Forecast, by Deployment Model

14.4.9.7. Market Revenue and Forecast, by End User

14.4.10. South Africa

14.4.10.1. Market Revenue and Forecast, by AI Technology

14.4.10.2. Market Revenue and Forecast, by Drug Development Stage

14.4.10.3. Market Revenue and Forecast, by Immunotherapy Type

14.4.10.4. Market Revenue and Forecast, by Cancer Type

14.4.10.5. Market Revenue and Forecast, by Application

14.4.10.6. Market Revenue and Forecast, by Deployment Model

14.4.10.7. Market Revenue and Forecast, by End User

14.4.11. Rest of MEA

14.4.11.1. Market Revenue and Forecast, by AI Technology

14.4.11.2. Market Revenue and Forecast, by Drug Development Stage

14.4.11.3. Market Revenue and Forecast, by Immunotherapy Type

14.4.11.4. Market Revenue and Forecast, by Cancer Type

14.4.11.5. Market Revenue and Forecast, by Application

14.4.11.6. Market Revenue and Forecast, by Deployment Model

14.4.11.7. Market Revenue and Forecast, by End User

14.5. Latin America

14.5.1. Market Revenue and Forecast, by AI Technology

14.5.2. Market Revenue and Forecast, by Drug Development Stage

14.5.3. Market Revenue and Forecast, by Immunotherapy Type

14.5.4. Market Revenue and Forecast, by Cancer Type

14.5.5. Market Revenue and Forecast, by Application

14.5.6. Market Revenue and Forecast, by Deployment Model

14.5.7. Market Revenue and Forecast, by End User

14.5.8. Brazil

14.5.8.1. Market Revenue and Forecast, by AI Technology

14.5.8.2. Market Revenue and Forecast, by Drug Development Stage

14.5.8.3. Market Revenue and Forecast, by Immunotherapy Type

14.5.8.4. Market Revenue and Forecast, by Cancer Type

14.5.8.5. Market Revenue and Forecast, by Application

14.5.8.6. Market Revenue and Forecast, by Deployment Model

14.5.8.7. Market Revenue and Forecast, by End User

14.5.9. Rest of LATAM

14.5.9.1. Market Revenue and Forecast, by AI Technology

14.5.9.2. Market Revenue and Forecast, by Drug Development Stage

14.5.9.3. Market Revenue and Forecast, by Immunotherapy Type

14.5.9.4. Market Revenue and Forecast, by Cancer Type

14.5.9.5. Market Revenue and Forecast, by Application

14.5.9.6. Market Revenue and Forecast, by Deployment Model

14.5.9.7. Market Revenue and Forecast, by End User

Chapter 15. Company Profiles

15.1. Exscientia

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. Insilico Medicine

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. Recursion Pharmaceuticals

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. Lantern Pharma

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. Atomwise

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. Generate Biomedicines

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. Cellworks Group

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. Ardigen

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. Owkin

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. CureMatch

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms